Martin Stuschke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Martin Stuschke has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
V. Budach
5 shared publicationsV Budach
4 shared publicationsW Budach
4 shared publicationsH Sack
3 shared publicationsW. Budach
Charité University Hospital, Berlin, Germany; Essen University Hospital, Essen, Germany; Tuebingen University Hospital, Tuebingen, Germany; Dresden University Hospital, Dresden, Germany; Erlangen University Hospital, Erlangen, Germany
3 shared publicationsA. Sak
2 shared publications
Latest Publications
- Open Access
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S323-S324
PO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S323-S324
Open AccessPO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC
- 1 August 2006
- Published by Springer Nature in Der Onkologe
- Vol. 12 (8) , 753-760
Nichtkleinzelliges Lungenkarzinom im Stadium III
- 1 August 2006
- Published by Springer Nature in Der Onkologe
- Vol. 12 (8) , 753-760
Nichtkleinzelliges Lungenkarzinom im Stadium III
- 1 November 2004
- Published by Springer Nature in Der Onkologe
- Vol. 10 (11) , 1179-1190
Neoadjuvante Radiochemotherapie und Responseprädiktion
- 1 November 2004
- Published by Springer Nature in Der Onkologe
- Vol. 10 (11) , 1179-1190
Neoadjuvante Radiochemotherapie und Responseprädiktion
- 31 August 2004
- Published by Elsevier in Lung Cancer
- Vol. 45, S133-S137
Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule
- 31 August 2004
- Published by Elsevier in Lung Cancer
- Vol. 45, S133-S137
Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 5503
Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95–06 Multicentre Trial
5503 Purpose: Is accelerated hyperfractionated radiation therapy with 70.6 Gy plus concurrent 5-FU/MMC (C-HART) more effective than a dose escalated HART scheme with 77.6 Gy alone? Material/Methods: The treatment consisted of 70.6 Gy plus 5-FU/MMC (C-HART) versus a 10% dose escalated HART of 77.6 Gy alone. Concurrently with C-HART MMC at a dosage of 10mg/m2 on days 5 and 35 and 5-FU at a dosage of 600mg/m2 as 120 hrs. c.i. during days 1–5 were delivered. Macroscopic tumor manifestations received 70.6 Gy (C-HART) or 77.6 Gy (HART), lymphatic drainage with high or low risk of metastatic spread, 60 Gy and 50 Gy, respectively. Results: The median follow-up period was 60 months for 384 patients, which were all analyzed according to the intent to treat principle. 84% of all patients were males, 16% females. 59.5% of all patients suffered from oropharyngeal, 32.4% from hypopharyngeal and 8.3% from oral cavity tumors. 93.8% of all patients (n=350) were diagnosed with stage IV and only 6.2% (n=23) with stage III. Patients were stratified according to tumor site, N-stage and participating centre. The actuarial locoregional control, overall and progressionfree survival rates at 5 years for C-HART versus HART, respectively, were 49.9% (95% CI: 42.3–58.7%) vs. 37.4% (95% CI: 30.4–46.0%, p=0.0009), 28.6% (95% CI:22.5–36.3%) vs. 23.7% (95% CI: 18.2–30.9%, p=0.02) and 29.3% (95% CI: 23.0–37.3%) vs. 26.6% (95% CI: 20.7–34.3%, p=0.009). The median LRC-period was 48 months vs. 15 mos., the OS-period 23 mos. vs. 16 mos.and the PFS-period 16 vs. 11 mos. for C-HART vs. HART, respectively. The actuarial freedon from metastases rates (C-HART vs. HART), were 51.9% (95% CI: 43.5–61.9%) vs. 54.7% (95% CI: 46.1–64.9%, p=0.58). Five and eight items, which were documented for acute and late normal tissue reactions, respectively, showed no significant difference between both treatment arms indicating equitoxicity and late morbidity. Conclusions: At equitoxic levels of acute and late normal tissue reactions for both treatment arms, C-HART is more effective than HART in all endpoints with the exception of the MFS-rates indicating an improvement of the therapeutic ratio. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 5503
Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95–06 Multicentre Trial
5503 Purpose: Is accelerated hyperfractionated radiation therapy with 70.6 Gy plus concurrent 5-FU/MMC (C-HART) more effective than a dose escalated HART scheme with 77.6 Gy alone? Material/Methods: The treatment consisted of 70.6 Gy plus 5-FU/MMC (C-HART) versus a 10% dose escalated HART of 77.6 Gy alone. Concurrently with C-HART MMC at a dosage of 10mg/m2 on days 5 and 35 and 5-FU at a dosage of 600mg/m2 as 120 hrs. c.i. during days 1–5 were delivered. Macroscopic tumor manifestations received 70.6 Gy (C-HART) or 77.6 Gy (HART), lymphatic drainage with high or low risk of metastatic spread, 60 Gy and 50 Gy, respectively. Results: The median follow-up period was 60 months for 384 patients, which were all analyzed according to the intent to treat principle. 84% of all patients were males, 16% females. 59.5% of all patients suffered from oropharyngeal, 32.4% from hypopharyngeal and 8.3% from oral cavity tumors. 93.8% of all patients (n=350) were diagnosed with stage IV and only 6.2% (n=23) with stage III. Patients were stratified according to tumor site, N-stage and participating centre. The actuarial locoregional control, overall and progressionfree survival rates at 5 years for C-HART versus HART, respectively, were 49.9% (95% CI: 42.3–58.7%) vs. 37.4% (95% CI: 30.4–46.0%, p=0.0009), 28.6% (95% CI:22.5–36.3%) vs. 23.7% (95% CI: 18.2–30.9%, p=0.02) and 29.3% (95% CI: 23.0–37.3%) vs. 26.6% (95% CI: 20.7–34.3%, p=0.009). The median LRC-period was 48 months vs. 15 mos., the OS-period 23 mos. vs. 16 mos.and the PFS-period 16 vs. 11 mos. for C-HART vs. HART, respectively. The actuarial freedon from metastases rates (C-HART vs. HART), were 51.9% (95% CI: 43.5–61.9%) vs. 54.7% (95% CI: 46.1–64.9%, p=0.58). Five and eight items, which were documented for acute and late normal tissue reactions, respectively, showed no significant difference between both treatment arms indicating equitoxicity and late morbidity. Conclusions: At equitoxic levels of acute and late normal tissue reactions for both treatment arms, C-HART is more effective than HART in all endpoints with the exception of the MFS-rates indicating an improvement of the therapeutic ratio. No significant financial relationships to disclose.
- 1 December 2003
- Published by Elsevier in Lung Cancer
- Vol. 42 (2) , 53-56
Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer
- 1 December 2003
- Published by Elsevier in Lung Cancer
- Vol. 42 (2) , 53-56
Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer
- 1 February 2002
- Published by Georg Thieme Verlag KG in Laryngo-Rhino-Otologie
- Vol. 81 (2) , 106-110
Brachytherapie mit 192Iridium bei lokalen Rezidiven von Nasopharynxkarzinomen
Hintergrund: Für die Therapie lokal rezidivierender Nasopharynxkarzinome stehen mehrere Modalitäten zur Verfügung, die kontrovers diskutiert werden. Zum einen besteht je nach der Vorbelastung durch die primäre Radiotherapie, die die Therapie der Wahl bei Nasopharynxkarzinomen darstellt, u. U. die Möglichkeit der erneuten perkutanen Bestrahlung z. B. im Rahmen der stereotaktischen Konvergenzbestrahlung. Zum zweiten gibt es bei kleinen Rezidiven auch die Möglichkeit der Operation. Darüber hinaus bietet sich die Brachytherapie an, da durch den steilen Dosisgradienten auch bei Vorbestrahlung u. U. eine erneute Strahlentherapie mit bestmöglicher Schonung des umgebenden dosislimitierenden Gewebes (wie des Sehnervs) möglich ist. Methode: Bei der Brachytherapie eines lokalen Rezidivs eines Nasopharynxkarzinoms wird zunächst ein ausreichend großer Zugang zum Nasopharynx geschaffen. Dieser dient einerseits der Platzierung des Applikators, andererseits erreicht man hierdurch auch eine Reduktion der Tumormasse. Über einen individuell angefertigten Applikator, der den im Magnet-Resonanz-Tomogramm (MRT) ermittelten anatomischen Erfordernissen angepasst wird, wird im Afterloadingverfahren die Strahlenquelle (192Iridium) an den Tumor gebracht. Die Brachytherapie hat den Vorteil, dass aufgrund des steilen Dosisgradienten eine relativ hohe Dosis direkt am Tumor appliziert werden kann. Nach histologischer Sicherung des Rezidives wurden in der Zeit zwischen 2/90 und 12/96 13 Patienten, 10 Männer und 3 Frauen, mit diesem Verfahren behandelt. Ergebnisse: Das Durchschnittsalter bei Therapiebeginn lag im Median bei 56 Jahren (37- 66 Jahre), der durchschnittliche Nachbeobachtungszeitraum betrug 49,7 Monate (8 -123 Monate). Histologisch lag 2-mal ein nicht verhornendes und 11-mal ein undifferenziertes Karzinom vor. Bei der Nachuntersuchung lebten noch 5 der 13 behandelten Patienten. Die 5-Jahres-Überlebenswahrscheinlichkeit betrug 46 %. 3 Patienten sind 5 Jahre und länger nach Therapie rezidivfrei. Die Patienten erhielten je nach Vorbelastung 2 - 6-mal eine Afterloadingtherapie mit einer jeweils applizierten Dosis von 7 Gy in 5 mm Gewebetiefe. Schlussfolgerung: Die Ergebnisse zeigen, dass mit der vorgestellten Methode eine gute Palliation erreicht werden kann, wenn auch weitere Untersuchungen an einem größeren Kollektiv nötig sind. Background: Local recurrence of nasopharyngeal carcinomas can be treated in different ways. One option is re-irradiation e. g. as stereotactically guided convergent beam. An operative approach is possible in small recurrent tumours. Brachytherapy is a good alternative because of the steep dose gradient in the pre-irradiated area. Methods: First step is the creation of a wide approach to the nasopharynx. This leads to a tumour mass reduction and gives space for the applicator. The radioactive substance will be brought into contact with the tumour by an afterloading procedure. The advantage of this therapy is the possibility to protect the surrounding tissue whereas the tumour receives a relatively high dosage. Between 2/90 and 12/96 10 men and 3 women were treated according to this protocol. Results: The median age was 56 years (37- 66 years), the average follow-up period was 49,7 months (8 -123 months). 2 non keratinising and 11 undifferentiated carcinomas were treated. 5 of 13 patients were still alive at the end of the follow-up period. The 5 year over all survival rate was 46 %. 3 patients are free of disease for 5 years or longer. The patients were treated 2 to 6 times with 7 Gy in 5 mm depth. Conclusions: The results show that good palliation can be achieved by the applied method but larger studies are required to give a definite statement.
- 1 February 2002
- Published by Georg Thieme Verlag KG in Laryngo-Rhino-Otologie
- Vol. 81 (2) , 106-110
Brachytherapie mit 192Iridium bei lokalen Rezidiven von Nasopharynxkarzinomen
Hintergrund: Für die Therapie lokal rezidivierender Nasopharynxkarzinome stehen mehrere Modalitäten zur Verfügung, die kontrovers diskutiert werden. Zum einen besteht je nach der Vorbelastung durch die primäre Radiotherapie, die die Therapie der Wahl bei Nasopharynxkarzinomen darstellt, u. U. die Möglichkeit der erneuten perkutanen Bestrahlung z. B. im Rahmen der stereotaktischen Konvergenzbestrahlung. Zum zweiten gibt es bei kleinen Rezidiven auch die Möglichkeit der Operation. Darüber hinaus bietet sich die Brachytherapie an, da durch den steilen Dosisgradienten auch bei Vorbestrahlung u. U. eine erneute Strahlentherapie mit bestmöglicher Schonung des umgebenden dosislimitierenden Gewebes (wie des Sehnervs) möglich ist. Methode: Bei der Brachytherapie eines lokalen Rezidivs eines Nasopharynxkarzinoms wird zunächst ein ausreichend großer Zugang zum Nasopharynx geschaffen. Dieser dient einerseits der Platzierung des Applikators, andererseits erreicht man hierdurch auch eine Reduktion der Tumormasse. Über einen individuell angefertigten Applikator, der den im Magnet-Resonanz-Tomogramm (MRT) ermittelten anatomischen Erfordernissen angepasst wird, wird im Afterloadingverfahren die Strahlenquelle (192Iridium) an den Tumor gebracht. Die Brachytherapie hat den Vorteil, dass aufgrund des steilen Dosisgradienten eine relativ hohe Dosis direkt am Tumor appliziert werden kann. Nach histologischer Sicherung des Rezidives wurden in der Zeit zwischen 2/90 und 12/96 13 Patienten, 10 Männer und 3 Frauen, mit diesem Verfahren behandelt. Ergebnisse: Das Durchschnittsalter bei Therapiebeginn lag im Median bei 56 Jahren (37- 66 Jahre), der durchschnittliche Nachbeobachtungszeitraum betrug 49,7 Monate (8 -123 Monate). Histologisch lag 2-mal ein nicht verhornendes und 11-mal ein undifferenziertes Karzinom vor. Bei der Nachuntersuchung lebten noch 5 der 13 behandelten Patienten. Die 5-Jahres-Überlebenswahrscheinlichkeit betrug 46 %. 3 Patienten sind 5 Jahre und länger nach Therapie rezidivfrei. Die Patienten erhielten je nach Vorbelastung 2 - 6-mal eine Afterloadingtherapie mit einer jeweils applizierten Dosis von 7 Gy in 5 mm Gewebetiefe. Schlussfolgerung: Die Ergebnisse zeigen, dass mit der vorgestellten Methode eine gute Palliation erreicht werden kann, wenn auch weitere Untersuchungen an einem größeren Kollektiv nötig sind. Background: Local recurrence of nasopharyngeal carcinomas can be treated in different ways. One option is re-irradiation e. g. as stereotactically guided convergent beam. An operative approach is possible in small recurrent tumours. Brachytherapy is a good alternative because of the steep dose gradient in the pre-irradiated area. Methods: First step is the creation of a wide approach to the nasopharynx. This leads to a tumour mass reduction and gives space for the applicator. The radioactive substance will be brought into contact with the tumour by an afterloading procedure. The advantage of this therapy is the possibility to protect the surrounding tissue whereas the tumour receives a relatively high dosage. Between 2/90 and 12/96 10 men and 3 women were treated according to this protocol. Results: The median age was 56 years (37- 66 years), the average follow-up period was 49,7 months (8 -123 months). 2 non keratinising and 11 undifferentiated carcinomas were treated. 5 of 13 patients were still alive at the end of the follow-up period. The 5 year over all survival rate was 46 %. 3 patients are free of disease for 5 years or longer. The patients were treated 2 to 6 times with 7 Gy in 5 mm depth. Conclusions: The results show that good palliation can be achieved by the applied method but larger studies are required to give a definite statement.
- 1 January 2002
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 78 (9) , 807-819
Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the G2-phase checkpoint
To characterize the relationship between cell-cycle progression and radiation-induced apoptosis in NSCLC cell lines with different p53 status. Cell lines with functional (H460, A549) and non-functional p53 (H661 and H520) were irradiated with 20 Gy. Multiparameter flow-cytometry was used to follow the progression of synchronized cells through the cell cycle after irradiation. Delayed apoptosis was observed after cell-cycle progression beyond the G2 block, either in the late G2/M-phase of the same cell cycle being irradiated (H661, H520) or in the G1-phase of the subsequent cell cycle (H460, A549). The apoptotic fraction in H661 and H520 was 60-80% at 144h after irradiation, higher than in A549 and H460 (5 and 35%, respectively). As an alternative to apoptosis in cells cycling beyond the G2 restriction point, hyperploid cells were generated by all cell lines. Inhibition of cell-cycle progression through the G2/M-phase efficiently reduced the induction of late apoptosis. After irradiation in S-phase, 50-60% of cells with functional p53 remained arrested at the G2 restriction point until 144 h post-irradiation, while only 20% of the H661 or H520 did so. These data characterize radiation-induced apoptosis in NSCLC cell lines as a removal pathway of clonogenically inactivated cells secondary to cell-cycle progression beyond G2/M, and is unlikely to be a critical factor for cellular radiation sensitivity.
- 1 January 2002
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 78 (9) , 807-819
Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the G2-phase checkpoint
To characterize the relationship between cell-cycle progression and radiation-induced apoptosis in NSCLC cell lines with different p53 status. Cell lines with functional (H460, A549) and non-functional p53 (H661 and H520) were irradiated with 20 Gy. Multiparameter flow-cytometry was used to follow the progression of synchronized cells through the cell cycle after irradiation. Delayed apoptosis was observed after cell-cycle progression beyond the G2 block, either in the late G2/M-phase of the same cell cycle being irradiated (H661, H520) or in the G1-phase of the subsequent cell cycle (H460, A549). The apoptotic fraction in H661 and H520 was 60-80% at 144h after irradiation, higher than in A549 and H460 (5 and 35%, respectively). As an alternative to apoptosis in cells cycling beyond the G2 restriction point, hyperploid cells were generated by all cell lines. Inhibition of cell-cycle progression through the G2/M-phase efficiently reduced the induction of late apoptosis. After irradiation in S-phase, 50-60% of cells with functional p53 remained arrested at the G2 restriction point until 144 h post-irradiation, while only 20% of the H661 or H520 did so. These data characterize radiation-induced apoptosis in NSCLC cell lines as a removal pathway of clonogenically inactivated cells secondary to cell-cycle progression beyond G2/M, and is unlikely to be a critical factor for cellular radiation sensitivity.
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S109
484: Association of tumour growth on nude mice and poor outcome in soft tissue sarcoma (STS) patients
- 30 September 1997
- Published by Elsevier in European Journal of Cancer
- Vol. 33, S109
484: Association of tumour growth on nude mice and poor outcome in soft tissue sarcoma (STS) patients
- 1 April 1997
- Vol. 29 (2) , 187-95
Ultrastructural evidence for divergent and alternating differentiations in spindle cell sarcoma xenografts.
Seven spindle cell sarcomas, 5 poorly differentiated ones and 2 moderately well differentiated ones, were established on nude mice and long term passaging was done. Sarcoma strains were analysed electron microscopically in an attempt to get further insight in spindle cell sarcoma differentiation pathways. Ultrastructurally, the tumours were classified as malignant peripheral nerve sheath tumour (3/7), leiomyosarcoma (2/7), rhabdomyosarcoma (1/7), and spindle cell sarcoma not otherwise classifiable (1/7). Undifferentiated tumour cells including fibroblastoid ones predominated in most xenografts, whereas cells harbouring cytoplasmic specificities tended to be few in number. Nevertheless, divergent differentiations exhibiting unusual double or triple patterns could be documented ultrastructurally in 12/30 xenografts with juxtaposed myomatous as well as nerve sheath-like cells and, in addition, histiocytoid (MFH-like) elements in 3 of the xenografts. Moreover, sarcoma strains alternated fine structural constellations in the course of passaging, whereby different phenotypes, myomatous, nerve sheath-like, unspecific, or mixed ones, succeeded one another. These findings pursue recent immunohistochemical data on multidirectional sarcoma differentiation by means of electron microscopy. They, furthermore, fit well into the concept of multipotential stem cells as progenitors in mesenchymal differentiation and suggest microenvironment to play a modifying role in the expression of cell differentiation.
- 1 April 1997
- Vol. 29 (2) , 187-95
Ultrastructural evidence for divergent and alternating differentiations in spindle cell sarcoma xenografts.
Seven spindle cell sarcomas, 5 poorly differentiated ones and 2 moderately well differentiated ones, were established on nude mice and long term passaging was done. Sarcoma strains were analysed electron microscopically in an attempt to get further insight in spindle cell sarcoma differentiation pathways. Ultrastructurally, the tumours were classified as malignant peripheral nerve sheath tumour (3/7), leiomyosarcoma (2/7), rhabdomyosarcoma (1/7), and spindle cell sarcoma not otherwise classifiable (1/7). Undifferentiated tumour cells including fibroblastoid ones predominated in most xenografts, whereas cells harbouring cytoplasmic specificities tended to be few in number. Nevertheless, divergent differentiations exhibiting unusual double or triple patterns could be documented ultrastructurally in 12/30 xenografts with juxtaposed myomatous as well as nerve sheath-like cells and, in addition, histiocytoid (MFH-like) elements in 3 of the xenografts. Moreover, sarcoma strains alternated fine structural constellations in the course of passaging, whereby different phenotypes, myomatous, nerve sheath-like, unspecific, or mixed ones, succeeded one another. These findings pursue recent immunohistochemical data on multidirectional sarcoma differentiation by means of electron microscopy. They, furthermore, fit well into the concept of multipotential stem cells as progenitors in mesenchymal differentiation and suggest microenvironment to play a modifying role in the expression of cell differentiation.